Literature DB >> 18481170

Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics.

Lina Mu1, Dionyssios Katsaros, Andrew Wiley, Lingeng Lu, Irene A Rigault de la Longrais, Stephanie Smith, Sapna Khubchandani, Olga Sochirca, Riccardo Arisio, Herbert Yu.   

Abstract

PURPOSE: To measure peptide concentrations and mRNA expression of the IGF Family in breast cancer and to examine their associations with the disease features. EXPERIMENTAL
DESIGN: Fresh tumor samples were collected from 348 patients who underwent surgery for breast cancer. Tissue levels of mRNA and peptide of IGF-I, IGF-II, and IGFBP-3 were analyzed with real-time RT-PCR and ELISA, respectively. Cox proportional hazards regression model was used to examine the associations of IGF markers with patient survival.
RESULTS: Age was inversely associated with IGF-I, IGF-II and IGFBP-3 at both mRNA and peptide levels. Small tumors, early TNM stages, or low grades were associated with high mRNA expression of IGFs and IGFBP-3. Hormone receptors were positively correlated with IGF-I and IGF-II expression. Survival analysis showed that patients with high expression of one of the IGF-I transcripts, IGF-IA, had lower risk of disease recurrence (HR = 0.47, 95%CI: 0.27-0.81) and death (HR = 0.35, 95%CI: 0.18-0.70) compared to those with low expression. High IGFBP-3 expression was also inversely associated with reduced risk of death (HR = 0.47, 95%CI: 0.23-0.95). Similar associations, however, were not observed when tissue levels of IGF-I peptide or IGFBP-3 protein were analyzed. High IGF-II peptide was related to increased risk of relapse (HR = 1.91, 95%CI: 1.12-3.27).
CONCLUSION: Our findings of high mRNA expression of IGFs and IGFBP-3 being associated with less aggressive tumors and favorable prognosis were consistent with previous observations, but were not supported by the measurement of tissue levels of IGF-I peptide and IGFBP-3 protein, suggesting that IGF mRNA expression and tissue levels of IGF peptides are regulated by different mechanisms and assessing these molecules in tumor tissue may have different implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481170     DOI: 10.1007/s10549-008-0046-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Authors:  Jie Tian; Thomas R Berton; Stephanie H Shirley; Isabel Lambertz; Irma B Gimenez-Conti; John DiGiovanni; Kenneth S Korach; Claudio J Conti; Robin Fuchs-Young
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

2.  Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.

Authors:  F Morgillo; F De Vita; G Antoniol; M Orditura; P P Auriemma; M R Diadema; E Lieto; B Savastano; L Festino; M M Laterza; A Fabozzi; J Ventriglia; A Petrillo; F Ciardiello; A Barbarisi; F Iovino
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

3.  Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; C Garberoglio; D De León
Journal:  Growth Horm IGF Res       Date:  2010-01-25       Impact factor: 2.372

Review 4.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

5.  Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome.

Authors:  Lingeng Lu; Chong Zhang; Gongjian Zhu; Melinda Irwin; Harvey Risch; Guido Menato; Marco Mitidieri; Dionyssios Katsaros; Herbert Yu
Journal:  Breast Cancer Res       Date:  2011-06-06       Impact factor: 6.466

6.  The prognostic values of insulin-like growth factor binding protein in breast cancer.

Authors:  Jiao Wang; Xin-Xin Luo; Yun-Liang Tang; Ji-Xion Xu; Zhen-Guo Zeng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.

Authors:  Ruoyi Zheng; Wenming Chen; Weiting Xia; Jingyu Zheng; Qing Zhou
Journal:  Biomed Res Int       Date:  2020-11-16       Impact factor: 3.411

8.  TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival.

Authors:  L Mu; D Katsaros; L Lu; M Preti; A Durando; R Arisio; H Yu
Journal:  Br J Cancer       Date:  2008-09-30       Impact factor: 7.640

9.  Assessment of IGF-1 expression in the peripheral blood of women with recurrent breast cancer.

Authors:  Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Francisco Adelton Alves-Ribeiro; Larysse Cardoso Campos-Verdes; Elmo de Jesus Nery Junior; Samara Fernanda Vieira-Valença; Rodrigo Jose de Vasconcelos-Valença; Veronica Mendes Soares; André Luiz Pinho-Sobral; Emerson Brandão Sousa; Pedro Vitor Lopes-Costa; Alesse Ribeiro Dos Santos; Jackeline Lopes Viana; Arquimedes Cavalcante Cardoso; Victoria Maria Luz-Borges; Renato de Oliveira Pereira; Cleciton Braga Tavares; Vladimir Costa Silva; Dorival Mendes Rodrigues-Junior; Luiz Henrique Gebrim; Benedito Borges da Silva
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.